• Home
  • Search Results

Search Results

Young Adult (18-34)
2353 studies match your search
Open

Study for Patients with Non-small Cell Lung Cancer

Have you been diagnosed with Stage III non-small cell lung cancer? Is your cancer advanced and not able to to removed? If so, you might be able to participate in a study that looks at a study drug to see if it can help the radiation treatment work better against your cancer.

Age & Gender
  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Cancer (Lung)
Not currently enrolling

Dose-escalation and expansion study of BAY 3375968 (anti-CCR8 antibody) as monotherapy and in combination with pembrolizumab in selected advanced solid tumors

This study will evaluate BAY 3375968 as a new immunotherapeutic agent in advanced solid tumor settings of high medical need.

Age & Gender
  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Cancer (Bladder, Breast, Colorectal, and 5 more)
Open

Liver Cancer Screening Study

If you have liver cirrhosis or chronic hepatitis B infection, you may qualify to participate in a research study that compares the effectiveness of two liver cancer screening methods. Please contact the study team to get more information. Compensation provided.

Age & Gender
  • 18 years ~ 85 years
  • Male, Female, Gender Inclusive
Study Interest
  • Stomach, Digestion and Gut Health
Open

PRevention Of Frailty with Fisetin (PROFFi) in Breast Cancer Survivors

Are you a breast cancer survivor? if soy you may be eligible to participate in this research study that is looking at the effectiveness of fisetin and/or exercise on physical function assessed using a 6 minute walking distance in chemotherapy-treated postmenopausal breast cancer survivors

Age & Gender
  • 18 years ~ 70 years
  • Female, Gender Inclusive
Study Interest
  • Cancer (Breast)
Not currently enrolling

Akero 106

We are studying an investigational drug, Efruxifermin, to see if it will help in the treatment of liver inflammation and scarring (fibrosis) in adults diagnosed with Compensated Cirrhosis due to NASH (non-alcoholic steatohepatitis) and MASH (metabolic dysfunction-associated steatohepatitis).

Age & Gender
  • 18 years ~ 80 years
  • Male, Female, Gender Inclusive
Study Interest
  • Kidneys and Liver
Open

An Open-Label, Multicenter, First-in-Human, Dose-Escalation, Multicohort, Phase 1/2 Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab in Subjects With Locally Advanced or Metastatic Solid Tumors

Do you have With Locally Advanced or Metastatic Solid Tumors of the Head or Neck? If so, you may be able to participate in a research study to to determine the safety profile and identify the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of INBRX 106 administered as a single agent or in combination with the anti-PD-1 checkpoint inhibitor (CPI) pembrolizumab (Keytruda®).

Age & Gender
  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Cancer (Head and Neck)
Open

Immune Functioning and Social Reward Processing in Autism and Typical Development

Are you interested in learning more about how the body and brain influences social behavior? If you are between 18 and 29 years old, you may be eligible to participate in our new EEG study! This project uses EEG and blood assaying techniques to understand how differences in immune functioning relates to the way that reward is processed in the brain. Compensation is provided.

Age & Gender
  • 18 years ~ 29 years
  • Male, Female, Gender Inclusive
Study Interest
  • Brain, Head, Nervous System
  • Immune System/Infections
  • UNC or UNC Health employees
  • and 3 more
Open

EFFICACY AND SAFETY OF DIVARASIB VERSUS SOTORASIB OR ADAGRASIB IN PATIENTS WITH NON-SMALL CELL LUNG CANCER

Do you have non small cell lung cancer? Are you currently not on any other treatments for your cancer? If you answered yes, you may be able to take part in a lung cancer medication study.

Age & Gender
  • 18 years ~ 99 years
  • Male, Female
Study Interest
  • Cancer (Lung)
Not currently enrolling

Metastatic Non-small Cell Lung Cancer Treatment

In this study, we want to see how patients with metastatic non-small cell lung cancer do with two treatments: ivonescimab and chemotherapy. We are comparing these treatments to find out which one helps patients more.

Age & Gender
  • 18 years ~ 99 years
  • Male, Female
Study Interest
  • Cancer (Lung)
Not currently enrolling

Young Adult Alcohol Harm Reduction Workshops

We are conducting 3 90-minute workshops with young adults who consume alcohol to support the development of an intervention to reduce alcohol use and prevent alcohol-related harms.

Age & Gender
  • 18 years ~ 25 years
  • Male, Female, Gender Inclusive
Study Interest
  • Behavior
  • Substance Use (tobacco, alcohol, opioids, etc)
Visit Location
Research for Me logo

Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH.  This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.

Questions?

  • This email address is being protected from spambots. You need JavaScript enabled to view it.
logo for the North Carolina Translational and Clinical Sciences Institute
logo for UNC Health
logo for UNC School of Medicine
logo for UNC Research